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Abstract
Background: Sufentanil is commonly used for analgesia and sedation during extracorporeal membrane
oxygenation (ECMO). Both ECMO and the pathophysiological changes derived from critical illness have significant
effects on the pharmacokinetics (PK) of drugs, yet reports of ECMO and sufentanil PK are scarce. Here, we aimed to
develop a population PK model of sufentanil in ECMO patients and to suggest dosing recommendations.
Methods: This prospective cohort PK study included 20 patients who received sufentanil during venoarterial ECMO
(VA-ECMO). Blood samples were collected for 96 h during infusion and 72 h after cessation of sufentanil. A
population PK model was developed using nonlinear mixed effects modelling. Monte Carlo simulations were
performed using the final PK parameters with two typical doses.
Results: A two-compartment model best described the PK of sufentanil. In our final model, increased volume of
distribution and decreased values for clearance were reported compared with previous PK data from non-ECMO
patients. Covariate analysis showed that body temperature and total plasma protein level correlated positively with
systemic clearance (CL) and peripheral volume of distribution (V2), respectively, and improved the model. The
parameter estimates of the final model were as follows: CL = 37.8 × EXP (0.207 × (temperature − 36.9)) L h−1, central
volume of distribution (V1) = 229 L, V2 = 1640 × (total plasma protein/4.5)2.46 L, and intercompartmental clearance
(Q) = 41 L h−1. Based on Monte Carlo simulation results, an infusion of 17.5 μg h−1 seems to reach target sufentanil
concentration (0.3–0.6 μg L−1) in most ECMO patients except hypothermic patients (33 °C). In hypothermic patients,
over-sedation, which could induce respiratory depression, needs to be monitored especially when their total
plasma protein level is low.
Conclusions: This is the first report on a population PK model of sufentanil in ECMO patients. Our results suggest
that close monitoring of the body temperature and total plasma protein level is crucial in ECMO patients who
receive sufentanil to provide effective analgesia and sedation and promote recovery.
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Background
Venoarterial extracorporeal membrane oxygenation
(VA-ECMO) is a temporary mechanical circulatory sup-
port for patients with cardiac failure [1, 2]. Because
ECMO is invasive, analgesia and sedation are important
to limit responsiveness, prevent accidental decannula-
tion, and maintain ECMO flows, all of which promote
recovery [3–5]. The use of opioids is standard practice
during ECMO [6–8].
Sufentanil is a synthetic opioid drug, which has a rapid
onset and is 5–10 times more potent than fentanyl [9].
It is highly protein bound (91–93%) [10], metabolised by
the liver, and excreted as metabolites in the urine (2%
unchanged, 80% metabolites) [11]. A large variability in
sufentanil pharmacokinetics (PK) is expected in ECMO
patients due to the combination of ECMO, drug charac-
teristics, and disease factors [12]. Volume of distribution
(Vd) is altered owing to physiologic changes related to
critical illness, hemodilution, and sequestration in
ECMO circuit, while clearance (CL) is variable owing to
organ dysfunction and non-pulsatile flow in VA-ECMO
[13–15]. ECMO could act as a reservoir that prolongs
the effect of sedatives even after the drugs have been dis-
continued [16]. Despite the widespread use of ECMO,
the literature regarding sufentanil PK and ECMO was
based on only in vitro analysis, which showed 83% loss
of sufentanil in ECMO circuits at 24 h [17]. In the
present study, we aimed to develop a population PK
model of sufentanil in ECMO patients and identify co-
variates associated with sufentanil exposure in order to
suggest a more rational dosing recommendation.
Methods
Study design and ethics approval
This was a prospective, cohort study conducted at
the cardiac intensive care unit in Severance Cardio-
vascular Hospital, a university-affiliated tertiary care
hospital in Seoul, Republic of Korea, between Janu-
ary 2016 and June 2017. The study was approved by
the Institutional Review Board (IRB No.: 4-2014-
0919) of Severance Hospital and was registered at
Clinicaltrials.gov (NCT02581280). Written informed
consent was obtained from the patients or the legal
surrogates of unconscious patients. This study com-
plied with the Strengthening the Reporting of Obser-
vational studies in Epidemiology (STROBE).
Study population
Twenty patients aged 19 years or older, who received
sufentanil-based analgesia and sedation during VA-
ECMO, were enrolled in this study. The exclusion cri-
teria were younger than 19 years, known allergy to
sufentanil, and taking any medication that could cause
potential drug-drug interactions or alter sufentanil
concentrations.
Dosing, administration, and data collection
ECMO patients received sufentanil for maintenance of
analgesia and sedation supplemented as needed with
midazolam. Sufentanil dosing in our centre was based
on patients’ body weight, with initial infusion doses of
12.5 (< 60 kg) or 17.5 μg h−1 (≥60 kg). An initial bolus of
3 (< 60 kg) or 5 mg (≥ 60 kg) midazolam was given, with
an initial infusion dose of 4.5 mg h−1. Management of
pain should be guided by routine pain assessment of
Nonverbal Pain Scale. Nurses assessed the depth of sed-
ation, indicating the prevalent Richmond Agitation Sed-
ation Scale (RASS) in their work shift. Analgesia and
sedation protocol was to keep patients deeply sedated
during the first few days of ECMO followed by inter-
mediate or light sedation before ECMO discontinuation
when possible. The infusion rates of sufentanil and mid-
azolam were modified to achieve a target RASS score,
and each dose adjustment was recorded.
Data on demographics, organ function, ECMO, vital
signs, and drug dosing were collected from the elec-
tronic medical records.
Extracorporeal membrane oxygenation
The ECMO circuit included a centrifugal blood pump
with a pump controller (Capiox® SP-101, Terumo Inc.,
Tokyo, Japan), an air-oxygen mixer (Sechrist® Ind., Ana-
heim, CA, USA), and conduit tubing (Capiox® EBS Cir-
cuit with X coating, Terumo Inc.). The days on ECMO,
ECMO flow rate, and ECMO pump speed were
recorded.
Sample collection and plasma concentration assay
The study was initiated during the first 48 h of starting
ECMO. Blood samples were collected after 3 and 12 h of
infusion and then every 24 h until 96 h had elapsed.
When infusion was discontinued for any reason, blood
was sampled after 0, 0.5, 1, 2, 6, and 12 h, and then every
24 h until 72 h had elapsed. Each blood sample (2 mL)
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was drawn from an existing arterial line and collected in
a tube containing ethylenediaminetetraacetic acid as an
anticoagulant. The blood samples were centrifuged at
1500×g for 10 min at 4 °C, and the plasma was immedi-
ately stored at − 80 °C until needed.
The plasma concentrations of sufentanil were analysed
using a validated HPLC system (Agilent Technologies,
CA, USA) coupled with a 4000 Qtrap liquid
chromatograph-mass spectrometer (ASICX, Concord,
Ontario, Canada). The plasma samples were denatured
with acetonitrile containing 0.5 μg mL−1 prazosin as an
internal standard. The mixture was vortexed and centri-
fuged at 150,000×g for 10 min at 4 °C. HPLC was per-
formed on a Kinetex C18 analytical column (4.6 × 50
mm; particle size 2.6 μm; Phenomenex, Torrance, CA,
USA) with a mobile phase consisting of 0.1% formic acid
in acetonitrile at a flow rate of 0.055 mLmin−1. The
lower limit of quantification for sufentanil was 0.02 μg
L−1. The assay was validated between 0.02 and 10 μg L−1
with inter- and intra-assay coefficients of variation of <
15%.
Population PK model development
The population PK model was developed using a first-
order conditional estimation method with an interaction
(FOCE+I) algorithm in the nonlinear mixed effects mod-
elling software NONMEM® version 7.4 (ICON Develop-
ment, Ellicott City, MD, USA). Pirana® ver. 2.9.2 and
Xpose® ver. 4.0 (http://xpose.sourceforge.net) in R® ver.
3.2.4 (http://www.r-project.org) were used to visualise
and evaluate the models. One-, two-, and three-
compartment models were evaluated as the structural
PK models. Inter-individual variability (IIV) for the PK
parameters was modelled assuming a log-normal distri-
bution: θi = θPop × EXP(ηi), where θi is the individual
value of the parameter θ in the ith individual, θPop is the
population value of this parameter, and ηi is a random
variable with mean zero and variance ωη
2 [18]. Propor-
tional models for residual variability was used: cij = cpij ×
(1 + εij) in which cij is the jth observed concentration of
the ith individual, cpij is the corresponding predicted
concentration, and εij is a random variable with mean
zero and variance σ2.
The likelihood ratio test was used to evaluate statistical
significance between nested models where a decrease in
the objective function value (OFV), a statistical equivalent
to the − 2 log likelihood of the model, of at least 3.84 was
considered statistically significant for an added parameter
(χ2 distribution, degrees of freedom (df) = 1, p < 0.05). In
addition, bias of the goodness-of-fit plots (observed versus
population predicted concentrations, observed versus in-
dividual predicted concentrations, conditional weighted
residuals (CWRES) versus population predicted concen-
trations, and CWRES versus time after dosing), visual
improvement of individual plots, confidence intervals of
parameter estimates, and shrinkage were assessed. The
aim of this study was to examine the potential effect of
various covariates of the model structural parameters. The
following covariates were investigated: sex, age, weight,
lean body weight, body mass index, tympanic body
temperature, total plasma protein, partial pressure of car-
bon dioxide, plasma pH, estimated glomerular filtration
rate, serum creatinine, total bilirubin, alanine transamin-
ase, aspartate transaminase, use of continuous renal re-
placement therapy, ECMO pump speed, and ECMO flow
rate. The estimated parameters were plotted against each
covariate to identify its influence. Continuous covariates
(Cov) were incorporated into the structural model with
centering on their median values within the population
and tested using power (1), linear (2), and exponential (3)
equations:
θPop ¼ θTV  Cov=Median Covð Þf gθCov ð1Þ
θPop ¼ θTV þ θCov  Cov−Median Covð Þf g ð2Þ
θPop ¼ θTV  EXP θCov  Cov=Median Covð Þð Þ ð3Þ
where θTV is the typical value of the parameter and θCov
quantifies the covariate effect. The covariate model
building was carried out in a stepwise process. In the
forward selection, a P value of < 0.05 was used (a de-
crease in OFV of at least 3.84, df = 1), while in the back-
ward elimination, a P value of < 0.01 was applied (a
decrease in the OFV of at least 6.64, df = 1).
Model evaluation and simulations
To evaluate stability in the final model, a non-stratified
bootstrap analysis was performed using the PsN Toolkit
[19]. A bootstrap with 5000 runs was performed on the
final model to evaluate the internal validity of the par-
ameter estimates and their corresponding 95% confi-
dence intervals (CIs). The model performance was
evaluated by means of prediction-corrected visual pre-
dictive checks (pc-VPCs). One thousand datasets were
simulated from the final model, and the median and
90% CI of the simulated data were plotted along with
the observed concentrations. To illustrate the effect of
body temperature and total plasma protein level on pre-
dicted sufentanil concentrations, Monte Carlo simulations
were performed using PK parameters from the final
model. We assumed that sufentanil was continuously in-
fused for 120 h with a rate of 12.5 or 17.5 μg h−1, which
were the doses most frequently used in our ECMO pa-
tients. The median parameter values for the patient popu-
lation were obtained with five different levels of body
temperature (33, 35, 36.7, 38 and 39 °C) and four different
total plasma protein levels (2, 4, 6, and 8 g dL−1) by simu-
lating 1000 individuals in each case.
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Results
Patients
Twenty ECMO patients were included, with a median
age of 55 years, median weight of 69.4 kg, and median
APACHE II score of 29 at the initiation of ECMO sup-
port. All the patients received mechanical ventilation
and started ECMO during the first 12 h after the onset
of myocardial infarction (MI). The median duration of
VA-ECMO and sufentanil infusion was 138 and 110 h,
respectively. Nine patients concurrently received con-
tinuous venovenous hemodiafiltration (CVVHDF) dur-
ing ECMO (Table 1). Desired sedation level was reached
or nearly reached (observed RASS = target RASS ± 1) in
all patients. A population PK analysis was conducted
with 106 plasma samples from the 20 patients. Concen-
tration records that were below the lower limit of quan-
tification were excluded from the analysis.
Population PK model building
A two-compartment model parameterised in terms of
systemic clearance (CL), central volume of distribution
(V1), peripheral volume of distribution (V2), and inter-
compartmental clearance (Q) was preferred to a one-
and three-compartment model. Residual variability was
described with a proportional residual error model. IIVs
were included for CL and V2, since they significantly im-
proved model performance. The structural model had
an OFV of − 343.1. In the univariate covariate analysis,
body temperature and total bilirubin were identified as
significant covariates of CL, resulting in a drop in OFV
of − 9.1 and − 6.0 points, respectively. In addition, total
protein and lean body weight were significant covariate
candidates of V2 with Δ OFVs of − 9.3 and − 3.4 points,
respectively. After the forward selection and backward
elimination, total bilirubin for CL and lean body weight
for V2 were removed.
Thus, the final PK model is described as follows:
CL = 37.8 × EXP (0.207 × (temperature − 36.9)) L h−1
V1 = 229 L
V2 = 1640 × (total plasma protein/4.5)2.46 L
Q = 41 L h−1
Model evaluation and simulation
The final parameter estimates and IIVs along with their
bootstrap CIs are provided in Table 2. All parameters
had acceptable relative standard error values. The
Table 1 Characteristics of the study patients
Number/median (range) (n = 20)
Age (years) 55 (23–88)
Male 16
Body weight (kg) 69.4 (52.9–92.5)
Lean body weight (kg) 55.3 (36.8–58.6)
Body mass index (kg m−2) 24.7 (20.5–31.8)
Indication for VA-ECMO
Acute myocardial infarction 4
ST-elevation myocardial infarction 12
Non-ST-elevation myocardial infarction 4
APACHE II 29 (15–36)
Time between onset of MI and initiation of ECMO (h) 2 (0.5–12)
Blood chemistry, serum levels
Total plasma protein (g dL−1) 4.5 (2.1–6)
Total bilirubin (mg dL−1) 1.9 (0.3–6.6)
Blood urea nitrogen (mg dL−1) 21.3 (7.5–58)
Serum creatinine (mg dL−1) 1.4 (0.4–4.9)
Partial pressure of carbon dioxide (mmHg) 29.1 (13.5–46.7)
Tympanic body temperature (°C) 36.9 (33–38.7)
Use of continuous venovenous hemodiafiltration 9
Duration of VA-ECMO (h) 138 (52.9–263)
ECMO flow rate (L min−1) 3 (0.6–4.1)
Duration of sufentanil infusion (h) 110 (34–260)
Sufentanil infusion rate
17.5 μg h−1 15
12.5 μg h−1 5
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population mean estimates were contained within the
95% CIs of the bootstrap results.
Figure 1 a–d show the goodness-of-fit plots. Both the
population predictions and individual predictions were
distributed relatively symmetrically around the line of
unity when plotted against the observations. In addition,
the CWRES versus time and versus population predic-
tions did not show any trends and were approximately
uniformly distributed around zero in the final model.
The pc-VPCs revealed that the 5th to 95th percentiles of
Table 2 Parameter estimates and bootstrap confidence intervals
Parameter Structural
model (RSE%)
[shrinkage%]
Final model
Final model
(RSE%)
[shrinkage%]
Bootstrap (5000 replicates)
Median 95% CI (2.5–97.5%)
Fixed effects
ΘCL 39.5 (11) 37.8 (3) 37.4 27.0, 47.8
ΘV1 220 (23) 229 (10) 223 66.2, 352
ΘV2 1620 (26) 1640 (9) 1629 755, 4304
ΘQ 35.8 (17) 41 (12) 42.1 21.5, 67.6
ΘTemp – 0.207 (5) 0.21 0.066, 0.437
ΘT.Prot – 2.46 (7) 2.51 0.892, 5.12
Random effects
Inter-individual variability
ωCL
2 0.196 (46) [15] 0.167 (57) [20] 0.197 0.03, 0.484
ωV2
2 1.41 (35) [21] 1.13 (48) [22] 0.968 0.081, 2.08
Residual variability
σ2proportional 0.0915 (19) [10] 0.0841 (5) [9] 0.0743 0.047, 0.116
RSE%, relative standard error; RSE% = (standard error/parameter estimate) × 100; CL, systemic clearance; V1, central volume of distribution; V2, peripheral volume of
distribution; Q, intercompartmental clearance
a b
c d
Fig. 1 Goodness-of-fit plots of the final population pharmacokinetic model. Log of observed sufentanil concentrations versus log of population
predicted concentrations (a) and versus log of individual predicted concentrations (b), and conditional weighted residuals (CWRES) versus
population predicted concentrations (c) and versus time (d)
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the predicted data overlaid most of the observed data,
indicating good precision of the PK model (Fig. 2). The
final covariate model was then used for simulations. Fig-
ure 3 shows the Monte Carlo simulated sufentanil con-
centrations during 120-h infusion using two different
dosing regimens, stratified by the body temperature and
total plasma protein level. The target concentrations
were set to 0.3–0.6 μg L−1. Overall, the concentrations of
sufentanil are increased in patients with low body
temperature and low total plasma protein levels.
Figure 3 a and c reveal the effect of different body
temperatures on sufentanil concentrations. With a dose
of 17.5 μg h−1, the concentrations of sufentanil from 24
to 120 h were within the target concentrations in
Fig. 2 Prediction-corrected visual predictive checks (pc-VPCs) of the final population pharmacokinetic model. Open circles, observed sufentanil
concentrations; solid line, median; lower and upper dashed lines, 5th and 95th percentiles of the simulated data, respectively; shaded areas, 95%
confidence intervals for simulated predicted median, 5th percentile, and 95th percentile constructed from 1000 simulated datasets of individuals
from the original dataset
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Fig. 3 Simulated mean sufentanil concentrations for 120-h sufentanil infusion in patients. Patients were stratified for body temperature (a, c) or
total plasma protein (b, d). a 12.5 μg h−1 infusion in patients with total plasma protein levels of 4.5 g dL−1. b 12.5 μg h−1 infusion in patients with
body temperatures of 36.9 °C. c 17.5 μg h−1 infusion in patients with total plasma protein levels of 4.5 g dL−1. d 17.5 μg h−1 infusion in patients
with body temperatures of 36.9 °C
Hahn et al. Critical Care          (2019) 23:248 Page 6 of 10
patients with a body temperature of 35–38 °C, whereas
they were above the target concentrations in patients de-
veloping hypothermia (33 °C) and under the target con-
centrations in patients with high fever (39 °C).
Figure 3b and d show the effect of different total
plasma protein levels on sufentanil concentrations. With
a dose of 17.5 μg h−1, sufentanil concentrations were
within target concentrations in most patients, whereas a
dose of 12.5 μg h−1 was low for patients with total
plasma protein levels of 4–8 g dL−1.
Discussion
We analysed a population of 20 critically ill ECMO pa-
tients who received sufentanil-based analgesia and sed-
ation, and we described a population PK model. A two-
compartment model with first-order elimination fitted
the time course of the total plasma sufentanil concentra-
tions best. In our final model, increased Vd (V1, 229 L;
V2, 1640 L, standardised total plasma protein level of
4.5 g dL−1) and decreased values for clearance (CL, 37.8
L h−1, standardised temperature of 36.9 °C; Q, 41 L h−1)
were reported compared with previous PK data from
non-critically ill patients (V1, 37.1 L; V2, 92.7 L; CL,
76.2 L h−1; Q, 52.2 L h−1) [20] and critically ill patients
not undergoing ECMO (Vd, 1582 L; CL, 56 L h−1) [21].
Sufentanil, as a highly lipophilic (logP = 3.24) and high
protein-binding (91–93%) drug [22], could be largely se-
questered in the ECMO circuit, which mimics an in-
crease in Vd [15]. Moreover, a systemic inflammatory
response, which can be triggered by the patient’s clinical
condition or the initiation of ECMO, alters permeability
of the blood-brain barrier and impacts the Vd of sufen-
tanil [13]. Decreased CL may have resulted from the re-
duced hepatic blood flow and impaired hepatic function
in critically ill patients [23]. Although nine patients re-
ceived CVVHDF concomitantly with ECMO, it would
have little effect on sufentanil PK. Primary mechanism
of sufentanil clearance is the liver. Also, the drug is lipo-
philic, exhibits highly protein binding, and has a rela-
tively high molecular weight (386.552 g/mol). Thus, it is
expected that sufentanil would not be removed by
CVVHDF, with limited clearance by VA-ECMO.
Body temperature and total protein level were found
to be significant covariates of sufentanil PK, and inter-
estingly, weight-related covariates were not included in
the final model. In previous sufentanil PK studies in pa-
tients undergoing coronary artery bypass surgery, adding
weight as a covariate showed neither a significant change
in log-likelihood nor an improvement in predictive abil-
ity due to the large impact of coronary artery bypass sur-
gery on sufentanil PK [16, 24]. Since ECMO also has a
large impact on sufentanil PK, we concluded that body
weight is rendered insignificant as a factor in our final
model.
The relationship between body temperature and sufen-
tanil systemic clearance was described as follows: CL =
37.8 × EXP (0.207 × (temperature − 36.9)) L h−1. These
results are in agreement with the findings of previous
studies, in which sufentanil showed decreased clearance
in hypothermic patients [25–27]. There are several pro-
cesses that may be responsible for a decrease in sufenta-
nil CL as body temperature drops. Sufentanil, a drug
with a high liver-extraction ratio (hepatic extraction ratio
of 0.7), is expected to be sensitive to blood flow alter-
ations [11]. When body temperature drops, total hepatic
blood flow is assumed to be markedly reduced [28],
which then reduces the hepatic elimination of sufentanil.
Furthermore, sufentanil metabolism occurs mainly via
the cytochrome P450 system (CYP450), which is known
to be strongly affected by temperature. Low temperature
changes the binding pocket confirmation of CYP3A4,
which reduces substrate affinity for CYP3A4 binding
sites and slows CYP3A4 metabolic activity [29]. In re-
cent studies, CYP3A4*1G genetic polymorphism was
found to be correlated with a lower amount of sufentanil
consumption due to impaired activity of CYP3A4 [30,
31]. The frequency of the CYP3A4*1G variant allele
showed big difference by ethnicity, which was 0.188–
0.279 in Chinese patients [32] and 0.079 in Caucasian
patients [33]. In further studies, CYP3A4 polymorphism
should be considered when extrapolating our data to
other patient groups.
The effect of temperature is especially relevant in
ECMO patients who show variability in body
temperature for many reasons. The body temperature of
ECMO patients could drop because of repeated blood
transfusion, infusion of fluid, severe infection, and sepsis.
In addition, to minimise brain damage, the body temper-
atures of ECMO patients after cardiac arrest are not
allowed to exceed 36 °C over 24 h. In contrast, some
ECMO patients could develop fever, which is associated,
for example, with inflammation, elevated sympathetic
tone, and catheter-related infections.
We also found that total plasma protein level was cor-
related positively with V2. Our results are different from
those of other studies, in which total protein level was
negatively correlated with V2 [34–36]. One teicoplanin
PK study demonstrated that a reduction in protein bind-
ing due to hypoproteinaemia could promote the distri-
bution of the free form of teicoplanin into extravascular
or intracellular spaces, thus increasing the volume of
distribution [35]. However, our finding could be ex-
plained by the fact that sufentanil binding is affected
mainly by the plasma concentration of α1-acid glycopro-
tein, and not by the total plasma protein level. Low total
protein levels might reflect impaired hepatic function,
which could produce low apparent volumes of distribu-
tion [37]. We want to highlight that our results are
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observatory and further studies are needed to fully un-
cover the relationship between total protein level and
volume of distribution. Furthermore, our estimates of
V2 shrinkage were relatively high (33%), so these esti-
mates should be interpreted with caution.
Targeted sufentanil plasma concentrations in critically
ill patients have not yet been determined accurately with
PK/pharmacodynamic studies. Pain and sedation man-
agement are important consideration in the care of the
ECMO patients, and no practice guidelines exist for this
population. Recent evidences suggest sedative/analgesic
protocols aiming for minimal and lighter sedation to im-
prove clinical outcomes [38, 39]. With limited data in pa-
tients with cardiac surgery together [40–43], we suggested
a target concentration between 0.3 and 0.6 μgmL−1 to en-
sure sedation and better clinical outcomes. Overall, an in-
fusion of 17.5 μg h−1 seems better than 12.5 μg h−1 in most
ECMO patients, except hypothermia patients (33 °C). In
hypothermic patients, over-sedation, which could induce
respiratory depression, needs to be monitored especially
when their total plasma protein level is low. With assess-
ment of the analgesia and sedative levels, dose reductions
should be considered. On the contrary, optimal levels of
analgesia and sedation could not be induced with com-
monly used doses in hyperthermic patients, which sug-
gests that an increased dose should be considered.
Our study did have several limitations. First, although the
hepatic clearance of sufentanil is largely dependent on hep-
atic plasma flow, we did not observe hepatic blood flow as
a potential covariate of CL in our PK model. Second, the
concomitant use of sedating and paralysing medications
prevented us from exploring the pharmacodynamics of
sufentanil in terms of the level of sedation and analgesia.
Future prospective studies that control for the presence of
concomitant sedating and paralysing agents and that meas-
ure the exact degree of sedation and analgesia score are
needed to link drug concentrations to the level of sedation
and analgesia to determine appropriate concentrations.
Nevertheless, the model developed in our study could be
used for future sufentanil dosing considerations and the de-
sign of clinical studies in patients using ECMO.
Conclusions
In conclusion, to the best of our knowledge, this is the
first report on a population PK model of sufentanil in
ECMO patients. The sufentanil volume of distribution
was increased, and clearance was decreased in VA-
ECMO patients compared with the values from previ-
ously reported non-ECMO patients. Body temperature
and total plasma protein level correlated positively with
CL and V2, respectively. The influence of body
temperature and total plasma protein on the PK of
sufentanil should be considered. Further research should
focus on the pharmacodynamics of sufentanil, such as
sedation and analgesia levels and haemodynamic stability
in patients during VA-ECMO.
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